Novo’s Next GLP-1 Just Hit 89% A1c Target

Novo Nordisk’s next-generation triple-agonist zenagamtide just hit 89.1% A1c target attainment in phase 2 — one of the highest rates ever reported for a Type 2 diabetes therapy, per the ADA 2026 Scientific Sessions coverage and the Novo Nordisk pipeline announcement. In adults with Type 2 diabetes, the highest dose produced 14.6% body-weight loss and a 1.71% A1c reduction at 36 weeks, with 89.1% reaching A1c below 7% and 76.2% reaching A1c 6.5% or lower. For the 38 million Americans living with Type 2 diabetes, this is being framed as the next leap forward in Type 2 management. It is — for managing the disease. It is not, and cannot be, a reversal.

What Just Happened

The zenagamtide phase 2 results, presented at ADA 2026, showed strong glycemic and weight-loss efficacy for the once-weekly GLP-1/GIP/glucagon triple agonist in adults with Type 2 diabetes, as detailed in the Novo Nordisk pipeline page.

The headline numbers from the ADA 2026 coverage, Novo Nordisk pipeline announcement, and primary trial report:

  • Trial design: Phase 2, randomized, double-blind, placebo-controlled trial in adults with Type 2 diabetes and a baseline A1c of 7.8%.
  • A1c reduction: The highest dose produced a 1.71% A1c reduction at 36 weeks.
  • A1c target attainment: 89.1% of participants on the highest dose reached A1c below 7%, and 76.2% reached A1c 6.5% or lower
  • Weight loss: 14.6% body weight loss at 36 weeks on the highest dose, per the Novo Nordisk pipeline announcement.
  • Mechanism: Zenagamtide is a once-weekly injectable that activates three hormone receptors — GLP-1, GIP, and glucagon — to lower blood sugar, slow stomach emptying, reduce appetite, and increase energy expenditure.
  • The clinical interpretation: The 89.1% A1c target attainment rate is among the highest ever reported in a Type 2 diabetes phase 2 trial, supporting advancement to phase 3

The Question Nobody’s Asking

Here’s what every headline about the zenagamtide results is leaving out: even a 89% A1c target rate on a drug still manages diabetes. It does not reverse it.

Zenagamtide works by activating three hormone receptors — GLP-1, GIP, and glucagon — to lower blood sugar and drive weight loss. You inject it once a week. When you stop, the A1c climbs back. The weight comes back. The medication never addresses why your blood sugar was dysregulated in the first place — it overrides the symptom while the underlying insulin resistance keeps running the show.

What Reversal Actually Looks Like

At Diabetes Reversal Group, we measure reversal by a single, unblinking standard: A1c 6.4% or lower — off every diabetes medication — sustained.

The mechanism isn’t a molecule. It’s a system: a patented nutrition protocol (240 recipes, 7-day meal plans, telemedicine delivery, mobile app coaching) that reverses the underlying insulin resistance at the root. The world’s only patented protocol for Type 2 diabetes reversal (U.S. patent granted September 2020), validated by an independent study.

The Bottom Line

Novo’s next GLP-1 just hit 89% A1c target. It’s a real win for Type 2 management. A system that reverses the
disease is a different game entirely — one the pharmaceutical pipeline cannot build.

If you’re on metformin, a GLP-1, or insulin, and you’ve been told you’ll be on it for life, you owe it to yourself to
look at what’s actually possible. Watch our free webinar.

No pitch. Just the science, the data, and how to know if you’re an candidate.

By: Dr. Jeffrey Hockings / Co-Founder/CEO / Diabetes Reversal Group / Kristine Burke, MD / Chief Medical
Officer / Diabetes Reversal Group.